Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
hydrochloride hydromorphone + flurbiprofen axetil
The First People's Hospital of Lianyungang
Enhanced Recovery After Surgery
1 trial -
insulin lispro injection, exenatide injection
The First People's Hospital of Lianyungang
Diabetes Mellitus, Type 2
1 trial -
intravenous tranexamic acid (TXA) infusion
The First People's Hospital of Lianyungang
Spontaneous Intracranial Hemorrhage
1 trial -
iodixanol
The First People's Hospital of Lianyungang
Kidney Failure, Chronic
1 trial -
lorlatinib
The First People's Hospital of Lianyungang
NSCLC
1 trial -
low-dose ticagrelor
The First People's Hospital of Lianyungang
Platelet Reactivity
1 trial -
low-dose ticagrelor
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
minimally invasive cholecystolithotomy with gallbladder reservation
The First People's Hospital of Lianyungang
Gallstones
1 trial -
mouse nerve growth factor
The First People's Hospital of Lianyungang
Cerebral Small Vessel Diseases
1 trial -
neoadjuvant therapy
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma Resectable
1 trial -
prescribing anapproved drug, examination
The First People's Hospital of Lianyungang
Irritable Bowel Syndrome With Diarrhea
1 trial -
profound neuromuscular blockade
The First People's Hospital of Lianyungang
Profound Muscle Relaxation
1 trial -
quetiapine fumarate tablet (Seroquel)
The First People's Hospital of Lianyungang
Bipolar Disorder
1 trial -
rhGM-CSF group
The First People's Hospital of Lianyungang
Mycoses
1 trial -
rhTPO
The First People's Hospital of Lianyungang
Thrombocytopenia
1 trial -
rhTPO
The First People's Hospital of Lianyungang
Primary Immune Thrombocytopenia
1 trial -
rituximab combined with corticosteroids
The First People's Hospital of Lianyungang
Primary Membranous Nephropathy
1 trial -
ropivacaine
The First People's Hospital of Lianyungang
Injury of Upper Limb
1 trial -
semaglutide combined with metformin
The First People's Hospital of Lianyungang
Osteoporosis
1 trial -
sodium zirconium cyclic silicate
The First People's Hospital of Lianyungang
Potassium Imbalance
1 trial -
ticagrelor
The First People's Hospital of Lianyungang
Inflammation
1 trial -
18F-FDG
The First People's Hospital of Lianyungang
Tumor, Solid
1 trial -
68Ga-DOTA-NT-20.3
The First People's Hospital of Lianyungang
Pancreatic Ductal Adenocarcinoma
1 trial -
68Ga-Her2-affibody
The First People's Hospital of Lianyungang
Neoplasms
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources